Literature DB >> 18684744

Dose-related patterns of glucocorticoid-induced side effects.

D Huscher1, K Thiele, E Gromnica-Ihle, G Hein, W Demary, R Dreher, A Zink, F Buttgereit.   

Abstract

OBJECTIVE: To identify patterns of self-reported health problems relating to dose and duration of glucocorticoid intake in unselected patients with rheumatoid arthritis from routine practice.
METHODS: Data from 1066 patients were analysed. The clinical status and drug treatment were reported by the physician, health problems during the past 6 months by the patient using a comprehensive list of symptoms. Patients with ongoing glucocorticoid treatment for more than 6 months and current doses of less than 5, 5-7.5 and over 7.5 mg/day prednisone equivalent were compared with a group without any glucocorticoid treatment for at least 12 months.
RESULTS: The frequency of self-reported health problems was lowest in the group without glucocorticoid exposition and increased with dosage. Two distinct dose-related patterns of adverse events were observed. A "linear" rising with increasing dose was found for cushingoid phenotype, ecchymosis, leg oedema, mycosis, parchment-like skin, shortness of breath and sleep disturbance. A "threshold pattern" describing an elevated frequency of events beyond a certain threshold value was observed at dosages of over 7.5 mg/day for glaucoma, depression/listlessness and increase in blood pressure. Dosages of 5 mg/day or more were associated with epistaxis and weight gain. A very low threshold was seen for eye cataract (<5 mg/day).
CONCLUSION: The associations found are in agreement with biological mechanisms and clinical observations. As there is a paucity of real-life data on adverse effects of glucocorticoids prescribed to unselected groups of patients, these data may help the clinician to adapt therapy with glucocorticoids accordingly and improve the benefit-risk ratio.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18684744     DOI: 10.1136/ard.2008.092163

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  103 in total

1.  The relationship between disease activity and depressive symptoms severity and optimism--results from the IMPROVED study.

Authors:  L Heimans; K V C Wevers-de Boer; K Visser; H K Ronday; G M Steup-Beekman; M van Oosterhout; T W J Huizinga; E J Giltay; R C van der Mast; C F Allaart
Journal:  Clin Rheumatol       Date:  2013-07-24       Impact factor: 2.980

2.  Vitamin B12: a tunable, long wavelength, light-responsive platform for launching therapeutic agents.

Authors:  Thomas A Shell; David S Lawrence
Journal:  Acc Chem Res       Date:  2015-10-19       Impact factor: 22.384

3.  Cell-mediated assembly of phototherapeutics.

Authors:  Weston J Smith; Nathan P Oien; Robert M Hughes; Christina M Marvin; Zachary L Rodgers; Junghyun Lee; David S Lawrence
Journal:  Angew Chem Int Ed Engl       Date:  2014-08-22       Impact factor: 15.336

Review 4.  [Long-term glucocorticoid therapy : Is there a safe dosage?].

Authors:  C Strehl; F Buttgereit
Journal:  Internist (Berl)       Date:  2016-09       Impact factor: 0.743

5.  Clinical trials: Insufficient data on glucocorticoid use in RA trials.

Authors:  Rieke H E Alten
Journal:  Nat Rev Rheumatol       Date:  2011-06       Impact factor: 20.543

6.  Novel views on new-onset diabetes after transplantation: development, prevention and treatment.

Authors:  Manfred Hecking; Johannes Werzowa; Michael Haidinger; Walter H Hörl; Julio Pascual; Klemens Budde; Fu L Luan; Akinlolu Ojo; Aiko P J de Vries; Esteban Porrini; Giovanni Pacini; Friedrich K Port; Adnan Sharif; Marcus D Säemann
Journal:  Nephrol Dial Transplant       Date:  2013-01-17       Impact factor: 5.992

7.  Risk factors for cataracts in systemic lupus erythematosus (SLE).

Authors:  Khaled Alderaan; Vuk Sekicki; Laurence S Magder; Michelle Petri
Journal:  Rheumatol Int       Date:  2014-09-26       Impact factor: 2.631

8.  Macrophage migration inhibitory factor inhibits the antiinflammatory effects of glucocorticoids via glucocorticoid-induced leucine zipper.

Authors:  Huapeng Fan; Wenping Kao; Yuan H Yang; Ran Gu; James Harris; Günter Fingerle-Rowson; Richard Bucala; Devi Ngo; Elaine Beaulieu; Eric F Morand
Journal:  Arthritis Rheumatol       Date:  2014-08       Impact factor: 10.995

9.  A double-blind randomized comparative study of triamcinolone hexacetonide and dexamethasone intra-articular injection for the treatment of knee joint arthritis in rheumatoid arthritis.

Authors:  Mehrzad Hajialilo; Amir Ghorbanihaghjo; Leyla Valaee; Sousan Kolahi; Naderh Rashtchizadeh; Maryam Bannazadeh Amirkhiz; Ida Malekmahdavi; Alireza Khabbazi
Journal:  Clin Rheumatol       Date:  2016-08-29       Impact factor: 2.980

10.  Analysis of the prevalence of cataracts and glaucoma in systemic lupus erythematosus and evaluation of the rheumatologists' practice for the monitoring of glucocorticoid eye toxicity.

Authors:  L Carli; C Tani; F Querci; A Della Rossa; S Vagnani; C Baldini; R Talarico; A d'Ascanio; R Neri; A G Tavoni; S Bombardieri; M Mosca
Journal:  Clin Rheumatol       Date:  2013-03-03       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.